MedTrace Logo

Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis

NCT01217125 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-03-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.

Conditions

  • Angiomyolipoma

Interventions

DRUG

Sirolimus

plasma levels between 4 and 8

Sponsors & Collaborators

  • Ministry of Health, Spain

    collaborator OTHER_GOV

  • Fundacio Puigvert

    lead OTHER

Principal Investigators

  • Roser Torra, MD,PhD · Fundacio Puigvert, Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01217125 on ClinicalTrials.gov